Monte Rosa Therapeutics I... (GLUE)
5.81
0.25 (4.50%)
At close: Jan 15, 2025, 11:41 AM
Cashflow (Annual)
Get detailed ratio statement breakdowns, uncovering price to free cash flow ratio, price per earnings, and much more.
| Year | FY23 | FY22 | FY21 | FY20 | FY19 |
| Net Income | -135.35M | -108.50M | -73.96M | -35.88M | -7.74M |
| Depreciation & Amortization | 6.22M | 3.75M | 2.13M | 537.00K | 72.00K |
| Stock-Based Compensation | 16.67M | 11.66M | 5.20M | 354.00K | n/a |
| Other Working Capital | 64.81M | -1.39M | 6.99M | 820.00K | -1.09M |
| Other Non-Cash Items | -3.81M | 2.76M | 960.00K | 7.68M | -276.00K |
| Deferred Income Tax | n/a | n/a | 17.00K | n/a | n/a |
| Change in Working Capital | 72.47M | -2.13M | 6.29M | 4.25M | 1.77M |
| Operating Cash Flow | -43.80M | -92.47M | -59.36M | -23.05M | -6.17M |
| Capital Expenditures | -19.04M | -12.91M | -9.73M | -3.39M | -1.39M |
| Acquisitions | n/a | 109.00K | 79.00K | n/a | n/a |
| Purchase of Investments | -103.15M | -384.42M | n/a | n/a | n/a |
| Sales Maturities Of Investments | 210.93M | 178.00M | n/a | n/a | n/a |
| Other Investing Acitivies | 62.00K | -206.31K | 79.00 | n/a | n/a |
| Investing Cash Flow | 88.80M | -219.22M | -9.65M | -3.39M | -1.39M |
| Debt Repayment | n/a | n/a | n/a | n/a | 750.00K |
| Common Stock Repurchased | n/a | n/a | n/a | -440.00K | n/a |
| Dividend Paid | n/a | n/a | n/a | n/a | n/a |
| Other Financial Acitivies | 27.49M | 411.00K | 139.81M | 60.50M | 14.25M |
| Financial Cash Flow | 27.49M | 20.47M | 377.56M | 60.06M | 15.00M |
| Net Cash Flow | 72.49M | -291.22M | 308.55M | 33.62M | 7.44M |
| Free Cash Flow | -62.84M | -105.38M | -69.09M | -26.44M | -7.56M |